Search research articles
Contact Us
Filters
Showing results (31-40 of 73) with videos related to
Page
of 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 22, 2022
Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia
Marina Konopleva, Michael J Thirman, Keith W Pratz, et al.
Haematologica
|
December 24, 2013
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms
Joshua F Zeidner, Judith E Karp, Amanda L Blackford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2016
Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms
Keith W Pratz, Brian D Koh, Anand G Patel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
September 25, 2019
A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation
Keith W Pratz, Michelle A Rudek, B Douglas Smith, et al.
British Journal of Haematology
|
May 19, 2012
Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias
Amer M Zeidan, Rebecca M Ricklis, Hetty E Carraway, et al.
Leukemia Research
|
September 14, 2016
Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies
Kelly J Norsworthy, Eunpi Cho, Jyoti Arora, et al.
Blood
|
August 6, 2009
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Patrick P Zarrinkar, Ruwanthi N Gunawardane, Merryl D Cramer, et al.
The Lancet. Oncology
|
January 18, 2018
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
Courtney D DiNardo, Keith W Pratz, Anthony Letai, et al.
Haematologica
|
October 13, 2022
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia
Keith W Pratz, Jason Kaplan, Moshe Levy, et al.
Blood
|
August 12, 2024
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
Hartmut Döhner, Keith W Pratz, Courtney D DiNardo, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 73) with videos related to
Sort By:
Page
of 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 22, 2022
Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia
Marina Konopleva, Michael J Thirman, Keith W Pratz, et al.
Haematologica
|
December 24, 2013
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms
Joshua F Zeidner, Judith E Karp, Amanda L Blackford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2016
Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms
Keith W Pratz, Brian D Koh, Anand G Patel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
September 25, 2019
A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation
Keith W Pratz, Michelle A Rudek, B Douglas Smith, et al.
British Journal of Haematology
|
May 19, 2012
Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias
Amer M Zeidan, Rebecca M Ricklis, Hetty E Carraway, et al.
Leukemia Research
|
September 14, 2016
Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies
Kelly J Norsworthy, Eunpi Cho, Jyoti Arora, et al.
Blood
|
August 6, 2009
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Patrick P Zarrinkar, Ruwanthi N Gunawardane, Merryl D Cramer, et al.
The Lancet. Oncology
|
January 18, 2018
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
Courtney D DiNardo, Keith W Pratz, Anthony Letai, et al.
Haematologica
|
October 13, 2022
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia
Keith W Pratz, Jason Kaplan, Moshe Levy, et al.
Blood
|
August 12, 2024
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
Hartmut Döhner, Keith W Pratz, Courtney D DiNardo, et al.
Page
of 8